M&A Deal Summary

Opko Acquires Bio-Reference Laboratories

On August 20, 2015, Opko acquired life science company Bio-Reference Laboratories for 1.5B USD

Acquisition Highlights
  • This is Opko’s 7th transaction in the Life Science sector.
  • This is Opko’s largest (disclosed) transaction.
  • This is Opko’s 6th transaction in the United States.
  • This is Opko’s 1st transaction in New Jersey.

M&A Deal Summary

Date 2015-08-20
Target Bio-Reference Laboratories
Sector Life Science
Buyer(s) Opko
Deal Type Add-on Acquisition
Deal Value 1.5B USD
Advisor(s) Allen & Company (Financial)
Davis Polk & Wardwell (Legal)

Target

Bio-Reference Laboratories

Elmwood Park, New Jersey, United States
website
Bio-Reference Laboratories, Inc. is a full service clinical diagnostic laboratory in the U.S. providing testing and related services to physician offices, clinics, hospitals, long term care facilities, employers, governmental units and correctional institutions.

Search 195,137 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Opko

Miami, Florida, United States

website


Category Company
Founded 1991
Sector Life Science
Employees5,269
Revenue 1.0B USD (2022)
DESCRIPTION
Opko's corporate headquarters in Miami, Florida.
Opko's corporate headquarters in Miami, Florida.

Opko is a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Opko's diagnostics business includes Bio-Reference Laboratories, a clinical laboratory with a core genetic testing business and a 420-person salesforce to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Opko's pharmaceutical business includes Rayaldee, a treatment for secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency and VARUBI for chemotherapy-induced nausea and vomiting. Opko's pharmaceutical business also includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection and a longer acting Factor VIIa drug for hemophilia. Opko was founded in 1991 and is based in Miami, Florida.


DEAL STATS #
Overall 18 of 20
Sector (Life Science) 7 of 9
Type (Add-on Acquisition) 16 of 18
State (New Jersey) 1 of 1
Country (United States) 6 of 7
Year (2015) 2 of 2
Size (of disclosed) 1 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-05-05 EirGen Pharma

Waterford, Ireland

EirGen Pharma Ltd. is a specialty pharmaceutical company focused on the development and commercial supply of high potency, high barrier to entry, pharmaceutical products for sale in the U.S., Canada, Japan, Australia, most European countries, and more than 40 others around the world.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-06-30 Transition Therapeutics

Toronto, Ontario, Canada

Transition Therapeutics Inc. is a bio pharmaceutical company, develops therapeutics for various disease indications. Transition Therapeutics, Inc. was formed in 1987 and is based in Toronto, Ontario.

Buy $60M